Cancer Genetics, Inc. (CGI) - DNA-based cancer diagnostics firm - works in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual. The firm was acquired by Gentris June 2014. Cancer Genetics, Inc. (CGI) had been focused to state-of-the-art diagnostic reagents and genetic diagnostics focused on cancer. CGI has established three complementary groups: * Probe Diagnostics * Genomic Research * Clinical Cytogenetics The Probe Diagnostics group has developed new reagents based on novel Fluorescence in situ Hybridization (FISH) technology for detecting non-random chromosomal abnormalities commonly encountered in multiple myeloma, leukemia, lymphomas, and solid tumors. The Genomic Research Group provides leading edge cytogenetic analyses for the research community. The Cytogenetic Services Group processes a variety of specimens using conventional G-banding and advanced molecular cytogenetic methods. The company's products and services provide more timely and accurate diagnostic and monitoring information to researchers and clinicians thereby allowing more effective patient treatment and improved outcomes.
